Pharmaceutical

Vanda and AnaptysBio link for generalised pustular psoriasis therapy

Vanda and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise imsidolimab to treat GPP.

Feb 5, 2025 - 06:00
Vanda and AnaptysBio link for generalised pustular psoriasis therapy
Vanda and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise imsidolimab to treat GPP.
Read the original article

Tags:

Previous Article

World Cancer Day: WHO warns of rising cancer burden in Southeast Asia

Next Article

Microplastics: the silent threat

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Intas Pharma employee used acid to destroy manufacturing records at troubled plant

STAT+: Intas Pharma employee used acid to destroy manuf...

Aug 1, 2023

Iovance’s PDUFA date for lifileucel pushed due to FDA backlog

Iovance’s PDUFA date for lifileucel pushed due to FDA b...

Sep 15, 2023

STAT+: If AI invents a new medicine, who gets the patent?

STAT+: If AI invents a new medicine, who gets the patent?

Jun 8, 2023